Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

By H. Kantarjian, N. Shah, J. Cortes, M. Baccarani, M. Agarwal, M. Undurraga, Jianxiang Wang, J. J. Kassack Ipiña, Dong-Wook Kim, M. Ogura and 10 more. Blood, 2012

612 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/5c53c983c97ebc9bf95e266651abee21f538c1d6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Cortes
2. Andreas Hochhaus
3. H. Kantarjian
4. M. Baccarani
5. Brian J. Druker

In Hematology

1. J. Cortes
2. J. Apperley
3. Andreas Hochhaus
4. J. Goldman
5. H. Kantarjian
6. M. Baccarani
7. Brian J. Druker

In Rheumatology

1. J. Cortes
2. Andreas Hochhaus
3. H. Kantarjian
4. M. Baccarani
5. Brian J. Druker

Citations in the corpus

• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, background): “It is recommended that in practice outside of clinical trials, the firstline treatment of CP CML can be any of the 3 TKIs that have been approved for this indication and are available nearly worldwide, namely imatinib (400mg once daily), nilotinib (300mg twice daily), and dasatinib (100 mg once dail”
• A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias (2013, neutral): “Neutropenia 44 (16) 38 (14) 22 (26) 22 (26) 14 (23) 11 (18) 4 (12) 4 (12)”
• Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012, neutral): “Omacetaxine 11 (17) 7 (16) 3 (33) 1 (12) 0”